In Batch 1 patients, five Th17-related cytokines were analyzed, and significantly higher levels of IL-22 were observed in the T2DM, CAD, and T2DM-CAD comorbidity patients than in the control individuals (Figure 1(b)). This evidence concerns the gene IL22 and coronary artery disorder.